Gemtesa’s manufacturer (Urovant Sciences) provides the Gemtesa Simple Savings Program. This is a financial assistance plan aimed at making Gemtesa (vibegron) — a treatment for overactive bladder in ...
On January 15, 2025, the U.S. Department of Health and Human Services Office of Inspector General (“OIG”) posted Advisory Opinion 25-01, a favorable opinion analyzing a pharmaceutical manufacturer’s ...
On June 17, 2024, the U.S. Department of Health and Human Services Office of Inspector General (“OIG”) posted a favorable Advisory Opinion 24-03 (“AO 24-03”) involving a pharmaceutical manufacturer’s ...
Pilot Study of a Mobile Phone Chatbot for Medication Adherence and Toxicity Management Among Patients With GI Cancers on Capecitabine Oral anticancer medications (OAMs) are high priced with a ...
Limited evidence from a literature review suggests that co-pay assistance was associated with improved treatment persistence/adherence across various diseases, with indirect evidence suggesting ...
When Gury Doshi, MD, learned that a patient’s insurance didn’t cover her breast cancer medication, Doshi had a potential workaround. The patient could try to bypass the insurer and access the drug at ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback